If you have symptoms of fever, cough or difficulty breathing, have traveled to areas impacted by the Coronavirus (2019-nCoV) within the past 14 days, and/or have been in close contact with someone who has traveled outside the US or been exposed to the Coronavirus please call your primary clinic before coming in for your appointment. We have also made temporary changes to who may accompany patients to appointments and treatments. Learn More

Treatments & Services

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

 

Bladder

  • IMMU-132 for Metastatic Urothelial Cancer

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)


Breast

  • Post-Mastectomy/Lumpectomy Radiation after Neoadjuvant Chemotherapy

    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy


Gastrointestinal

Head and Neck

Leukemia

Lung

  • Canakinumab for Adjuvant Non-Small Cell Lung Cancer

    A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer


Lymphoma

Pancreatic

Prostate

Solid Tumors

  • Cabozanitib +/- Atezolizumab in Solid Tumors

    A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors


  • AVID100 in Patients with Advanced or Metastatic Solid Tumors

    A phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100. an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin


  • INCMGA00012 in Solid Tumors

    A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors


  • Febrile Neutropenia Observational Trial

    A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN


  • MGCD516 for Solid Tumor Malignancies

    A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies